Artesunate/amodiaquine

Artesunate/amodiaquine
Package of medication in Nigeria
Combination of
ArtesunateAntimalarial
AmodiaquineAntimalarial
Names
Trade namesCamoquin, others[1]
Other namesASAQ
Clinical data
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    use    		By mouth[2]
    Defined daily doseNot established[3]

    Artesunate/amodiaquine, sold under the trade name Camoquin among others, is a medication used for the treatment of malaria.[4][5] It is a fixed-dose combination of artesunate and amodiaquine.[4] Specifically it recommended for acute uncomplicated Plasmodium falciparum malaria.[6] It is taken by mouth.[3]

    Common side effects include loss of appetite, nausea, abdominal pain, sleepiness, trouble sleeping, and cough.[7] Safety in pregnancy is not clear; however, the medication may be used if others are not possible.[7] It is believed to be safe for use during breastfeeding.[7] Artesunate and amodiaquine are both antimalarial medication; however, work by different mechanisms.[7]

    Artesunate/amodiaquine was commercially launched in 2007.[8] It is on the World Health Organization's List of Essential Medicines.[4] Artesunate/amodiaquine is available as a generic medication.[8] The wholesale cost in the developing world is about US$0.85 to US$1.52 for a course of treatment.[3] As of 2014 it is not commercially available in the United States or United Kingdom.[1][9]

    Medical uses

    Early clinical trials showed that a once-a-day dosage was effective.[10] It was subsequently shown to be equally effective as artemether/lumefantrine,[11] although it is likely to be more effective in the field due to its simpler once-a-day dosage compared to artemether/lumefantrine twice-per-day dosage.

    Dosage

    The defined daily dose is not established.[2] For those who weight more than 35 kg the dose is 200/540 mg one a day, for those who weight 18 to 35 kg the dose is 100/270 mg once a day, for those who weight 9 to 18 kg the dose is 50/135 mg once per day, and for those who weight 4.5 to 9 kg the dose is 25/67.5 mg once per day.[12] Treatment is for three days.[12]

    Society and culture

    Artesunate/amodiaquine was commercially launched in 2007 as an affordable treatment for malaria, devised by DNDi in partnership with Sanofi-Aventis.[8] ASAQ was handed over to the MMV Access and Product Management Team in May 2015.[13]

    References

    1. 1 2 Ainsworth, Sean B. (2014). Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life. John Wiley & Sons. p. 75. ISBN 9781118819517. Archived from the original on 2016-12-20.
    2. 1 2 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 19 August 2020. Retrieved 20 September 2020.
    3. 1 2 3 "Artesunate + Amodiaquine". International Drug Price Indicator Guide. Archived from the original on 22 January 2018. Retrieved 8 December 2016.
    4. 1 2 3 World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
    5. ↑ Oyakhirome S, Pötschke M, Schwarz NG, et al. (March 2007). "Artesunate--amodiaquine combination therapy for falciparum malaria in young Gabonese children". Malar. J. 6: 29. doi:10.1186/1475-2875-6-29. PMC 1831475. PMID 17352806.
    6. ↑ World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 187. hdl:10665/44053. ISBN 9789241547659.
    7. 1 2 3 4 "Artesunate Amodiaquine Winthrop" (PDF). WIPO. August 2010. Archived (PDF) from the original on 24 October 2016. Retrieved 12 December 2016.
    8. 1 2 3 "New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available – DNDi". www.dndi.org. 1 March 2007. Archived from the original on 20 December 2016. Retrieved 12 December 2016.
    9. ↑ Goldman, Lee; Schafer, Andrew I. (2015). Goldman-Cecil Medicine. Elsevier Health Sciences. p. 2112. ISBN 9780323322850. Archived from the original on 2016-12-20.
    10. ↑ Ndiaye, Jean; Randrianarivelojosia, Milijaona; Sagara, Issaka; Brasseur, Philippe; Ndiaye, Ibrahima; Faye, Babacar; Randrianasolo, Laurence; Ratsimbasoa, Arsène; Forlemu, Doris; Moor, Vicky; Traore, Aminata; Dicko, Yahia; Dara, Niawanlou; Lameyre, Valérie; Diallo, Mouctar; Djimde, Abdoulaye; Same-Ekobo, Albert; Gaye, Oumar (June 2009). "Randomized, multicentre assessment of the efficacy and safety of ASAQ – a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria". Malaria Journal. 8: 125. doi:10.1186/1475-2875-8-125. PMC 2698916. PMID 19505304. Archived from the original on 19 September 2011. Retrieved 18 January 2013.
    11. ↑ Nidiaye, Jean-Louis A; Faye, Babacar; Gueye, Ali; Tine, Roger; Ndiaye, Daouda; Tchania, Corinne; Ndiaye, Ibrahima; Barry, Aichatou; Cissé, Badara; Lameyre, Valérie; Gaye, Oumar (2011). "Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial". Malaria Journal. 10: 237. doi:10.1186/1475-2875-10-237. PMC 3171378. PMID 21838909. Archived from the original on 10 October 2014. Retrieved 18 January 2013.
    12. 1 2 "ARTESUNATE/AMODIAQUINE = AS/AQ oral - Essential drugs". medicalguidelines.msf.org. Archived from the original on 24 January 2021. Retrieved 25 August 2020.
    13. ↑ "DNDi passes the ball to MMV | Medicines for Malaria Venture". www.mmv.org. Archived from the original on 2020-02-13. Retrieved 2020-02-13.
    Identifiers:
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.